InflaRx N.V. (IFRX) stock

IFRXNasdaqPharmaceutical PreparationsFiscal year ends December 31

Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Mar 20, 2026Score 5/30

$1.17−0.07 (-5.65%)

Close on Nov 13, 2026Market cap $84.58MP/E –Yield –

InflaRx gross margin

Gross margin is gross profit as a percentage of revenue.

For fiscal 2025 it was -24677.9%, against -1900.8% the year before.

Period	Period end	Value	Change (pts)
FY2025	Dec 31, 2025	-24677.9%	−22777.2
FY2024	Dec 31, 2024	-1900.8%	−1157.1
FY2023	Dec 31, 2023	-743.7%	–

Change is against the same quarter a year earlier.

Period	Period end	Value	Change (pts)
Q2 FY2025	Jun 30, 2025	-5985.4%	–
Q2 FY2024	Jun 30, 2024	-5376.7%	–

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is IFRX.

Advertisement
300 × 250

See a number that looks wrong?